Zinger Key Points
- J&J is exploring the sale of Cerenovus, a stroke care business, in a deal potentially worth $1 billion to $1.5 billion.
- The company spent over $30 billion on medtech acquisitions in the past three years, including Abiomed and Shockwave Medical.
- Get real-time earnings alerts before the market moves and access expert analysis that uncovers hidden opportunities in the post-earnings chaos.
Johnson & Johnson JNJ is reportedly considering selling its stroke care unit, Cerenovus, in a deal that could value the business at more than $1 billion.
The move aligns with the company’s ongoing efforts to streamline its medical technology division following a series of acquisitions.
The healthcare giant has engaged advisers to gauge interest from private equity firms and strategic buyers.
Also Read: Johnson & Johnson’s MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Monday’s Financial Times report, citing sources, indicates that Cerenovus, which develops surgical tools for stroke treatment, could fetch between $1 billion and $1.5 billion.
Johnson & Johnson has aggressively expanded its medtech portfolio, spending over $30 billion on acquisitions in the past three years.
In 2022, Johnson & Johnson acquired Abiomed for an upfront payment of $380.00 per share, corresponding to an enterprise value of approximately $16.6 billion.
In 2024, Johnson & Johnson acquired Shockwave Medical for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including cash acquired.
In August, Johnson & Johnson made a tuck-in deal to acquire V-Wave for an upfront payment of $600 million, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion. V-Wave is a privately held medical device company focused on developing heart failure and cardiovascular disease treatment options.
In 2024, the company’s MedTech unit generated sales of $31.8 billion, up 4.8% or 6.2% operationally, with Shockwave and Abiomed as part of the primary operational drivers.
Citing Jefferies Analysts, the Financial Times report adds that Johnson & Johnson has one of the strongest cash and debt capacities for future deals.
Price Action: JNJ stock is down 0.49% at $155.36 during the premarket session on last check Wednesday.
Read Next:
Photo by Tada Images via Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
